May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Intravitreal Bevacizumab for Choroidal Neovascularization With Large Submacular Hemorrhage in Age-Related Macular Degeneration
Author Affiliations & Notes
  • M. B. Parodi
    Clinica Oculistica, Azienda Ospedaliero-Universit di Trieste, Trieste, Italy
  • P. Iacono
    Clinica Oculistica, Azienda Ospedaliero-Universit di Trieste, Trieste, Italy
  • G. Di Stafano
    Clinica Oculistica, Azienda Ospedaliero-Universit di Trieste, Trieste, Italy
  • A. Fachin
    Clinica Oculistica, Azienda Ospedaliero-Universit di Trieste, Trieste, Italy
  • P. Makovec
    Clinica Oculistica, Azienda Ospedaliero-Universit di Trieste, Trieste, Italy
  • G. Ravalico
    Clinica Oculistica, Azienda Ospedaliero-Universit di Trieste, Trieste, Italy
  • Footnotes
    Commercial Relationships  M.B. Parodi, None; P. Iacono, None; G. Di Stafano, None; A. Fachin, None; P. Makovec, None; G. Ravalico, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 2675. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. B. Parodi, P. Iacono, G. Di Stafano, A. Fachin, P. Makovec, G. Ravalico; Intravitreal Bevacizumab for Choroidal Neovascularization With Large Submacular Hemorrhage in Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2675. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To assess the effects of intravitreal bevacizumab (Avastin) injections in the treatment of choroideal neovascularization (CNV) with large submacular hemorrhage (LSH) secondary to age-related macular degeneration (AMD).

Methods: : Prospective interventional case series. Patients with occult CNV with LSH greater the 50% of the entire lesion were considered. The protocol required 3 monthly consecutive injections, followed by repeat injections over the 12-month follow-up on the basis of OCT parameters, angiographic features, visual acuity response.

Results: : Eight patients were enrolled in the study and prospectively followed up. Mean visual acuity and mean foveal thickness (FT) at baseline were 0.72±0.35 (logMAR±SD) and 296±86µm SD, respectively. At three-month examination, mean visual acuity improved to 0.46±0.28 SD and mean FT decreased to 240±105µm SD. At 12-month examination, mean visual acuity was 0.48±0.32 SD, and mean FT 238±50µm SD. A progressive resolution of macular bleeding was registered in 7 patients. Neither side-effect or complication was registered.

Conclusions: : Intravitreal bevacizumab seems to be a beneficial treatment for CNV with LSH secondary to AMD. A randomized clinical trial with greater number of patients and control group is needed to confirm our preliminary results.

Keywords: choroid: neovascularization • age-related macular degeneration • growth factors/growth factor receptors 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×